Peptide falls 30% after lead drug fails trial
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.IN A STARK reminder of the risks facing biotechnology companies, Cambridge-based Peptide Therapeutics yesterday saw its market capitalisation fall by a third after it announced it had ceased development of one of its lead drugs. The company is now worth just pounds 41.1m.
The shares closed down 25.5p at 52.5p after Peptide said its flagship decapeptide allergy vaccine had failed in late-stage clinical trials.
One analyst, who declined to be named, said: "The hit on the shares is not excessive. This was a major drug for the company and for it to fail in phase IIb trials is a real blow."
The drug was hoped to have a general applicability across a range of allergies from hayfever to asthma. It now appears the molecule upon which it was based is ineffective. The optimism surrounding the treatment was the reason for the foundation of Peptide in 1993.
Dr John Brown, chief executive, said the company still had other anti- allergy drugs in development through a collaborative research agreement with SmithKline Beecham.
"Whilst these trials have not produced the results that we anticipated, several promising alternatives are emerging from our research," he said.
"Peptide could be seeing sales in 2001."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments